Information Provided By:
Fly News Breaks for August 17, 2017
IMMU
Aug 17, 2017 | 09:10 EDT
Cowen analyst Philip Nadeau said the Immunomedics submission of IMMU-132 BLA is on track and he expects the company to release updated results during the second half of the year for submission in Q4 or Q1. The analyst continues to think the shares are significantly undervalued given the drug's potential. Nadeau reiterated his Outperform rating and $15 price target on Immunomedics shares.
News For IMMU From the Last 2 Days
There are no results for your query IMMU
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.